Navigation Links
Cytomegalovirus in Medical News

Viral Infection Might Trigger High Blood Pressure

... animal studies indicate. Mice infected with cytomegalovirus (CMV) were more likely to develop not only high ... a CMV vaccine. "It is virtually certain that cytomegalovirus infection makes at least some contribution to ... disease in people," Schleiss said. "Obviously, cytomegalovirus is not the whole picture. There are other issues, ...

ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients

... drug with a unique mechanism of action against cytomegalovirus and a favorable clinical safety profile to date, ... to current anti-CMV therapies. About cytomegalovirus CMV is a member of the herpes virus group, ... drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma ...

Cell death from cytomegalovirus may bring new life to treatment of retinal disease

... likely the body's well-intended effort to stop cytomegalovirus retinitis. "We can try to infect certain cells ... looking at mechanisms of retinal damage during cytomegalovirus infection," Dr. Atherton said. Tools include a ... blood and semen, it's most typically latent. cytomegalovirus retinitis' last big resurrection came with the ...

Also in the March 24 JNCI

... Human cytomegalovirus Stimulates Telomerase Activity in Tissue Culture Cells Infection with human cytomegalovirus (HCMV) triggers expression of the telomerase reverse transcriptase (hTERT) ...

Existing anti-obesity drugs may be effective against flu, hepatitis and HIV

... changes in metabolic flux in human cells as they become infected by human cytomegalovirus (HCMV), an enveloped virus of the b-herpes family that infects most human ... severe disease in those with weakened immune systems. Researchers chose cytomegalovirus for experiments because it serves as an excellent model for processes at ...

ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)

... has granted orphan drug designation for CAMVIA for the prevention of cytomegalovirus (CMV) disease in patients with impaired cell-mediated immunity. The ... of CMV that are resistant to commonly used anti-CMV drugs. About cytomegalovirus CMV is a member of the herpes virus group, which includes the ...

ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE, and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. diff . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Incorporated Reports Second Quarter 2009 Financial Results

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis

... and the ACR Pedi 70 response was reached by 48% and 73% respectively. Four patients (12%) developed mild adverse events: including one case of cytomegalovirus infection and three varicella zoster virus (VZV) infections. One patient experienced a serious adverse event and was hospitalised for a necrotising ...

ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma to Present at Two May Healthcare Conferences

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

American Cancer Society awards 143 research grants to investigators at 83 institutions nationwide

... patients. Charles Cobbs, M.D., California Pacific Medical Center, is testing the novel hypothesis that infection of cancer stem cells by human cytomegalovirus (HCMV) leads to the development of brain cancer. If true, currently available antiviral drugs or vaccines might be effective in the prevention and ...

First evidence for DNA-based vaccination against chronic hepatitis C

... study, researchers developed a T cell vaccine based on a codon-optimised HCV non-structural (NS) 3/4A DNA-gene expressed under the control of the cytomegalovirus immediate-early promoter (ChronVac-C) delivered by in vivo electroporation (EP). A first phase I/IIa clinical trial in HCV infected patients is ...

ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

Genetic evidence points to potential therapeutic bypass for autoimmune process

... Carma1 gene, which they named the king mutation. The researchers took the Carma1-deficient mice and infected them with a mouse variant of human cytomegalovirus which is related to herpes and chickenpox viruses and can remain dormant or cause serious illness in people with compromised immune systems. ...

CMV Infection in Solid Organ Transplantation: Clinical Clues and Prevention Strategies

... A Complimentary Continuing Medical Education Newsletter for Healthcare Professionals VOORHEES, N.J., Feb. 27 /PRNewswire/ -- cytomegalovirus (CMV) infection is an important cause of morbidity and mortality and is the most common viral opportunistic infection in recipients of solid organ ...

OHSU vaccine research targets HIV in the slower, early stage of infection

... used a monkey model of AIDS - simian immunodeficiency virus (SIV) the monkey counterpart to HIV. They introduced an altered monkey form of cytomegalovirus (CMV) programmed to express SIV proteins and trigger specialized effector memory T-cells to look for and attack SIV in its early stages. In total, ...

IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte(R) (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients

... extended preventative therapy ('prophylaxis') with Valcyte met its primary endpoint of reducing the number of kidney transplant patients who develop cytomegalovirus (CMV) disease within the first year post-transplant. Valcyte is indicated for the prevention of CMV disease in kidney, heart, and ...

ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

Poor people suffer disproportionately from chronic infections

... looked at H. Pylori, a bacterium that causes peptic ulcer disease; hepatitis A and B, which can cause liver disease; and herpes simplex 1 and cytomegalovirus (CMV), both implicated in cardiovascular disease, Alzheimer's disease and other ailments. Similarly, there is a large difference in the ...

ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile. ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Provides Update on Vancocin(R)

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

CMV Infection in Transplant Recipients: Clinical Cases and Expert Opinion

... A Complimentary Continuing Education Virtual Lecture for Healthcare Professionals VOORHEES, N.J., Dec. 15 /PRNewswire/ -- cytomegalovirus (CMV) infection is a serious condition and an important cause of morbidity and mortality in recipients of hematopoietic stem cell transplant (HSCT) ...

ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile. ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies

... methods of treating a broad spectrum of viral infections, including human immunodeficiency virus (HIV), influenza, hepatitis C virus (HCV) and cytomegalovirus (CMV), using one or more anti-phospholipid antibodies that directly bind to an aminophospholipid target, either alone or in combination with other ...

Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections

... program of the U.S. Defense Threat Reduction Agency (DTRA). Bavituximab and other anti-PS antibodies are also being studied preclinically in HIV, cytomegalovirus (CMV) and other serious viral infections. "Based on these findings, anti-PS antibodies such as bavituximab may represent a completely new ...

Vical Announces Strategic Restructuring and Staff Reduction

... its Allovectin- 7(R) immunotherapeutic currently in a pivotal Phase 3 trial in patients with advanced metastatic melanoma, and its DNA vaccine for cytomegalovirus (CMV), currently in a Phase 2 trial in stem cell transplant recipients. The company is exploring partnering opportunities for the congenital disease ...

ViroPharma Incorporated Reports Third Quarter 2008 Financial Results

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile. ViroPharma routinely posts information, including press releases, which may be important to investors in the investor ...

ASP announces 2008 T. Franklin Williams Scholars

... Hopkins University School of Medicine Immunology Dysregulations and Inflammation in the Pathogenesis of Frailty of Older Age: The Role of Chronic cytomegalovirus Infection ASP-American Geriatrics Society Foundation for Health in Aging Award ...

ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and C. difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com . ...

Virus mimics human protein to hijack cell division machinery

... MADISON - Viruses are masters of deception, duping their host's cells into helping them grow and spread. A new study has found that human cytomegalovirus (HCMV) can mimic a common regulatory protein to hijack normal cell growth machinery, disrupting a cell's primary anti-cancer mechanism. Writing in ...

ViroPharma Incorporated Reports First Quarter 2008 Financial Results

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and non-toxigenic C. difficile (NTCD). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . ...

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . Disclosure Notice ...

Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . ...

ViroPharma Augments Senior Management

... at http://www.viropharma.com/docs/Vancocin_pi_2007.htm ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . ...
Other Contents
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/10/2015)... 11, 2015 Fingerprint Cards (FPC) has ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... by smartphone manufacturers in China . The ... revenue guidance of + 1 000 MSEK for 2015.   ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/26/2015)... May 26, 2015 Hexagon Geospatial is ... Defence and Space in a new content-sharing program that ... for use in the development of smart applications. ... this partnership combines optical satellite data from Airbus Defence ... tear down the walls between geospatial content, software and ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 i2i Systems, ... solutions for more than 15 years, has earned 2014 ... Committee for Quality Assurance (NCQA) for its flagship product ... are proud of the work we have done to ... grateful for the acknowledgement from NCQA once again,” said ...
(Date:5/26/2015)... 2015 Scientists at the University of ... help advanced mesothelioma patients benefit from immunotherapy; surgery may ... article on the new research. Click here to ... of thoracic surgery and pulmonology theorized that, because large ... system attack, immunotherapy drugs might work better if the ...
(Date:5/26/2015)... 2015 ProTrailer Network is a new ... Pro X . This Effect includes 30 all ... styled text. , ProTrailer Network allows users to ... can easily complement any form of media project. FCPX ... can make professional looking openers. , ProTrailer Network includes ...
(Date:5/26/2015)... 2015 Learning ZoneXpress is excited to ... Education Cards . These cards have been specifically designed ... simple, easy-to-read text, these new educational resources are extremely ... practical nutrition tips and suggestions to clients and provide ... , + MyPlate: Eat for a Healthy Baby Pregnancy ...
Breaking Medicine News(10 mins):Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 2Health News:Hexagon Geospatial and Airbus Defense Establish Partnership 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2Health News:Learning ZoneXpress Introduces New Educational Resource for WIC, SNAP-Ed, and EFNEP 2
Other TagsOther Tags